The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 18, 2025
Filed:
Mar. 28, 2024
Applicant:
The Trustees of the University of Pennsylvania, Philadelphia, PA (US);
Inventors:
Marco Ruella, Ardmore, PA (US);
Saar Gill, Philadelphia, PA (US);
Carl H. June, Merion Station, PA (US);
Avery D. Posey, Philadelphia, PA (US);
Daniel J. Powell, Bala Cynwyd, PA (US);
Assignee:
The Trustees of the University of Pennsylvania, Philadelphia, PA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 35/17 (2015.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
C07K 16/2896 (2013.01); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464429 (2023.05); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 14/70507 (2013.01); C07K 14/7051 (2013.01); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); C07K 16/2803 (2013.01); C07K 16/2806 (2013.01); C12N 5/0636 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 14/4748 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01);
Abstract
The present invention includes compositions and methods for treating T cell lymphomas and leukemias. In certain aspects, the compositions and methods include CAR T cells targeting CD2, CD5, or CD7 and modified cells wherein CD2, CD5, or CD7 has been knocked-out.